Bacterial Conjunctivitis Clinical Trial
— BACTOvation™Official title:
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Verified date | May 2015 |
Source | NovaBay Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to evaluate the microbiological and clinical efficacy of Auriclosene compared to its vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either Auriclosene Ophthalmic Solution or Vehicle Ophthalmic Solution.
Status | Completed |
Enrollment | 217 |
Est. completion date | January 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 1 Year and older |
Eligibility |
Inclusion Criteria: - 1 year of age and older - Bulbar conjunctival injection - Conjunctival discharge/exudate - Signs and symptoms of bacterial conjunctivitis in at least one eye for 3 days or less - Other inclusion criteria per protocol Exclusion Criteria: - Suspected fungal, viral, Chlamydia or Acanthamoeba co-infection based on clinical diagnosis - Any drug treatment in either eye for the current episode of bacterial conjunctivitis prior to study enrollment - Other exclusion criteria per protocol |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
NovaBay Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Resolution of individual ocular signs and symptoms | 5 days | No | |
Primary | Microbiological Success | Eradication of all pre-therapy isolates | 5 days | No |
Secondary | Clinical Cure | Resolution of all signs and symptoms | 5 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00565123 -
Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis
|
Phase 2/Phase 3 | |
Completed |
NCT00972777 -
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
|
Phase 2/Phase 3 | |
Completed |
NCT00759148 -
Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT00798577 -
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
|
Phase 4 | |
Completed |
NCT00331916 -
AL-15469A for the Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT02432807 -
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT01573910 -
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
|
Phase 3 | |
Terminated |
NCT01330355 -
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT00332293 -
AL-15469A for the Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT03004924 -
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
|
Phase 3 | |
Completed |
NCT02980523 -
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
|
Phase 2 | |
Completed |
NCT01175590 -
Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
|
Phase 3 | |
Completed |
NCT00464438 -
A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
|
Phase 4 | |
Completed |
NCT00312338 -
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
|
Phase 4 | |
Recruiting |
NCT03235141 -
Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00105534 -
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
|
Phase 3 | |
Completed |
NCT00105469 -
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
|
Phase 3 | |
Recruiting |
NCT06363292 -
Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects.
|
Phase 1 | |
Withdrawn |
NCT01238783 -
Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis
|
Phase 2 | |
Terminated |
NCT01740388 -
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
|
Phase 3 |